

Serial No:
Filed:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

J1059 U.S. PTO
09/995217
11/27/01

APPLICATION OF: Andrew L. Pearlman
SERIAL NO: 09/537,004 GROUP ART UNIT: 3737
FILED: March 28, 2000 EXAMINER: Manuel, G.
BATCH NO. H43
CUSTOMER NO.: 27162
FOR: TISSUE CHARACTERIZATION BASED ON IMPEDANCE
IMAGES AND ON IMPEDANCE MEASUREMENTS
ATTY/DKT NO.: 701030-11

Box Issue Fee
Commissioner for Patents
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

____ §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

____ §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

____ The statement as specified in 37 CFR §1.97(e) set out below; OR

____ The fee of \$230.00 under 37 CFR §1.17(p).

Serial No:
Filed:

X §1.97(d)

This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$180.00 set out in 37 CFR §1.17(i).

X §1.97(e)


The undersigned Attorney hereby states that:

X each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

— no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.



#113106

Respectfully submitted,
Andrew L. Pearlman

William Squire
Reg. No. 25,378
CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Tel: (973)994-1700
Fax: (973)994-1744

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$180.00 set out in 37 CFR §1.17(i).

____ §1.97(e) The undersigned Attorney hereby states that:

- each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;
or
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.


Items 1 – 41 and 43 – 59 on Form 1449 were cited in the parent application and no copies are being provided herewith.

Items 43 – 45 and 64 – 66 were cited in a corresponding foreign filed application and copies are enclosed.

Items 42 and 63 were not previously cited and copies are enclosed.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Respectfully submitted,
Andrew L. Pearlman


William Squire
Reg. No. 25.378
CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Tel: (973)994-1700
Fax: (973)994-1744

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Andrew L. Pearlman
SERIAL NO: Not assigned GROUP ART UNIT: Not assigned
FILED: Herewith EXAMINER: Not assigned
CUSTOMER NO.: 27162
FOR: Tissue Characterization Based on Impedance Images and on
Impedance Measurements
ATTY/DKT NO.: 701030-13

J1059 U.S. PTO
09/995217
11/27/01

Box Patent Application
Commissioner for Patents
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

____ §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

____ The statement as specified in 37 CFR §1.97(e) set out below; OR

____ The fee of \$180.00 under 37 CFR §1.17(p).

____ §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;